Assay In Which An Enzyme Present Is A Label Patents (Class 435/7.9)
-
Patent number: 9222949Abstract: The present invention provides an immunoassay method for detecting or determining the amount of salvinorin A, salvinorin B and/or analogues thereof in an in vitro sample, an antibody for salvinorin A, salvinorin B and/or analogues thereof and a kit for detecting the presence of or determining the amount of salvinorin A, salvinorin B and its analogues thereof in a sample.Type: GrantFiled: April 27, 2010Date of Patent: December 29, 2015Assignee: RANDOX LABORATORIES, LTD.Inventors: Stephen P. Fitzgerald, Robert I. McConnell, Philip A. Lowry, Elouard Benchikh
-
Patent number: 9201070Abstract: The invention relates to an antigenic structure that contains a tryptophan epitope, characterised in that said structure is made up of a tryptophan pattern W or a peptide of 3 or 4 amino acids comprising a pattern W, coupled with glutaraldehyde. The invention can he used for screening trypanosomiasis in humans or animals.Type: GrantFiled: April 13, 2011Date of Patent: December 1, 2015Assignee: CENTRE DE COOPERATION INTERNATIONALE EN RECHERCHE AGRONOMIQUE POUR LE DEVELOPMENT (CIRAD)Inventors: Philippe Holzmuller, Silla Semballa, Philippe Vincendeau, Gerard Cuny
-
Patent number: 9198979Abstract: In one aspect, there is provided a protein-drug conjugate compound comprising a protein covalently attached by a linker to one or more drug moieties, wherein the linker has a half-life of from 1 hour to 50 hours in phosphate buffered saline at 37° C. A carbonyl derivative of LU103793 is also described that can be used in a protein-drug conjugate compound comprising an antibody covalently attached by a linker to the drug moiety comprising, consisting or consisting essentially of the carbonyl derivative.Type: GrantFiled: March 25, 2013Date of Patent: December 1, 2015Assignee: Philogen S.P.A.Inventor: Casi Giulio
-
Patent number: 9188594Abstract: The present invention relates to a device and method for determining the presence of a specific compound in solution. The device includes a nanosensor having an electrically conducting pathway between at least a first and second contact. The device also includes a first receptor, suitable for binding a specific compound in the solution, attached to the nanosensor, and a second receptor also suitable for binding the specific compound while the specific compound is bound to the first receptor. The second receptor is attached to an enzyme added to the solution. When the solution having the second receptor is added to the device, and a second compound that is a substrate for the enzyme is subsequently added to the solution, a measured difference in an electrical property in the device before and after the application of the second compound is indicative of the presence of the specific compound in the solution.Type: GrantFiled: August 4, 2009Date of Patent: November 17, 2015Assignee: Yale UniversityInventors: Tarek M. Fahmy, Eric D. Stern, Mark A. Reed, Aleksandar Vacic, James F. Klemic
-
Patent number: 9182397Abstract: The present invention relates to a device and method for detecting analytes in a sample.Type: GrantFiled: September 13, 2012Date of Patent: November 10, 2015Assignee: DSM IP ASSETS B.V.Inventors: Mylene Patrice Dominique Caussette, Stephen Ludovic Alexandre Hennart, Maartje Maria Franse
-
Patent number: 9161810Abstract: Apparatuses, compositions and methods for removing cells which interfere with regenerative processes. The apparatuses, compositions and methods selectively kill partially functional and/or non-functional cells versus functional cells while protecting functional proliferative cells to the extent that, upon removal of the killed cells by disintegration or scavenging, functional cells replace the partially- or non-functional cells.Type: GrantFiled: December 21, 2011Date of Patent: October 20, 2015Assignee: Siwa CorporationInventor: Lewis Gruber
-
Patent number: 9164091Abstract: A centrifugal micro-fluidic device detecting analytes in a liquid specimen and a method of detection of analytes from a liquid specimen using the micro-fluidic device are provided. Reaction efficiency is increased using a repetitive flow of the liquid specimen induced by an alternating combination of capillary force and centrifugal force, thereby enhancing detection sensitivity.Type: GrantFiled: January 12, 2011Date of Patent: October 20, 2015Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventor: In Wook Kim
-
Patent number: 9163070Abstract: New designed ankyrin repeat proteins with binding specificity for PDGF-BB are described, as well as nucleic acids encoding such PDGF binding proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.Type: GrantFiled: June 27, 2013Date of Patent: October 20, 2015Assignee: MOLECULAR PARTNERS AGInventor: Michael Baumann
-
Patent number: 9140684Abstract: The present technology relates generally to devices to expose cells to fluid shear forces and associated systems and methods. In particular, several embodiments are directed toward devices to expose cells to fluid shear forces in order to measure changes in internal cell forces. In some embodiments, a fluidic device includes a flow unit configured to induce fluid flow through the device. The device further includes a fluid channel configured to accept a biological sample dispersed on an array of flexible structures. The flow unit can be configured to induce disturbed and/or laminar flow in the fluid channel. The device can further include optical or magnetic detection means configured to measure a degree of deflection of one or more flexible structures in the array.Type: GrantFiled: October 29, 2012Date of Patent: September 22, 2015Assignee: University of Washington through its Center for CommercializationInventors: Nathan J. Sniadecki, Lucas Ting
-
Patent number: 9131929Abstract: Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings.Type: GrantFiled: April 5, 2011Date of Patent: September 15, 2015Assignee: STB, Ltd.Inventors: Martin MacPhee, Jerry Kanellos, Belinda Wilmer, Dawson Beall
-
Patent number: 9119870Abstract: A joint-lubricating composition for treating degenerative joint disorders is provided, having microalgal polysaccharides in an aqueous solution, wherein the polysaccharides are stable and non-immunogenic. Further provided is a method for treating a joint disorder by injecting into the joint a viscous aqueous solution of a polysaccharide, wherein the disorder is, for example, arthritis, and the polysaccharide originates, for example, from a red alga.Type: GrantFiled: December 7, 2006Date of Patent: September 1, 2015Assignee: Ben Gurion University of the Negev Research and Development AuthorityInventors: Shosh Arad, Dan Atar
-
Patent number: 9117967Abstract: [Problem] A problem is to provide a method of manufacturing a glass substrate with a concave-convex film using dry etching capable of giving a fine concave-convex structure precisely by dry etching, a glass substrate with a concave-convex structure, a solar cell, and a method of manufacturing a solar cell. [Means to Solve the Problem] In order to give a concave-convex structure to a glass substrate made of a plurality of oxides placed in different vapor pressures during dry etching, a subject film forming step and a concave-convex structure forming step are provided. The subject film forming step forms a subject film made of a single material on a flat surface of the glass substrate. The concave-convex structure forming step forms a periodic concave-convex structure in a surface of the subject film by dry etching. As a result, a fine concave-convex structure is formed precisely by dry etching.Type: GrantFiled: August 29, 2012Date of Patent: August 25, 2015Assignee: EL-SEED CORPORATIONInventors: Fumiharu Teramae, Koichi Naniwae, Tsukasa Kitano, Toshiyuki Kondo, Atsushi Suzuki, Midori Mori
-
Patent number: 9097731Abstract: A method for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pathologies potentiated by a heparin substance, such as thrombocytopenia induced by heparin (HIT type II) as inducer drug. The method includes the steps of reacting at least one substance with high affinity for a heparin substance (SFA), with at least one heparin substance (SH) so as to form a substance with high affinity for heparin-heparin substance (SFA-SH) complex. The heparin substance is adapted to bind other substances with affinity for heparin and with at least one potential antigenic substance capable of reacting with the heparin substance, forming a (Ag-SH) complex. The method further includes the steps of testing a patient's plasma or serum potentially containing an anti(Ag-SH) antibody after administration of the heparin substance and revealing the resulting (Ag-SH)-anti(Ag-SH) complex produced.Type: GrantFiled: June 25, 2007Date of Patent: August 4, 2015Assignee: Hypen BiomedInventors: Jean Amiral, Anne-Marie Vissac
-
Patent number: 9091687Abstract: An ELISpot diagnosis kit for NMO and its application are characterized in that, the polypeptide fragment specific to NMO effector T-cell is obtained through topological conformation analysis of aquaporin-4 (AQP-4), followed by the structural analyses of the related polypeptides after combination and rearrangement so as to screen out the brand-new polypeptide fragment suitable for NMO disease diagnosis. In the ELISpot experiment, by utilizing the obtained polypeptide fragment, stimulate the effector T-cell in the NMO disease to secrete IL-4, proving the feasibility and scientific value of that polypeptide fragment in the NMO diagnosis. This method is with strong specificity, high sensitivity and easy operations, and it can be developed into the diagnosis kit for the diagnosis and differential diagnosis of NMO in the clinical examination, laying the foundation for the early discovery and treatment of NMO.Type: GrantFiled: April 16, 2013Date of Patent: July 28, 2015Inventors: Jun Xu, Shuli Zhao, Xinxin Chen, Jianqun Shi, Yinwei Zhu, Yingdong Zhang, Yin Hong
-
Patent number: 9075017Abstract: An optical-waveguide sensor chip includes an optical waveguide having a first substance immobilized on the surface thereof, the first substance being specifically reactive with an analyte substance, and fine particles dispersed on the optical waveguide and having a second substance immobilized on the surface thereof, the second substance being specifically reactive with the analyte substance.Type: GrantFiled: December 26, 2013Date of Patent: July 7, 2015Assignee: KABUSHIKI KAISHA TOSHIBAInventors: Shingo Kasai, Ikuo Uematsu, Ichiro Tono, Tomohiro Takase, Isao Nawata, Kayoko Oomiya, Yuriko Oyama, Tsutomu Honjoh
-
Patent number: 9073995Abstract: Provided in the present invention are an aberrantly glycosylated integrin, AG-?3?1, and use thereof as a bladder cancer marker. Also provided in the present invention are a hybridoma cell generating an anti-AG-?3?1 monoclonal antibody, a monoclonal antibody BCMab1 secreted by the same, and use of BCMab1 in the preparation of a medicament for the treatment of bladder cancer. Also provided in the present invention is use of inhibitors of GAL3ST2 and N-acetylgalactosaminyltransferase 1 in the preparation of a medicament for the treatment of bladder cancer.Type: GrantFiled: August 12, 2011Date of Patent: July 7, 2015Assignee: Institute of Biophysics, Chinese Academy of SciencesInventors: Chong Li, Zusen Fan, Honglian Zhang, Zhonghua Dai, Haidong Tang, Jun Chen
-
Patent number: 9068995Abstract: The present invention comprises methods for determining the presence, amount, or concentration of analytes of interest including Vitamin D and other secosteroids from biological samples, through derivatization, with improved speed and ease of analysis and improved sensitivity to mass spectrometry. In a preferred embodiment, the present invention comprises methods for determining the presence, amount, or concentration of analytes of interest, including Vitamin D and other secosteroids from whole human blood, through derivatization, and using a plasma collection device to facilitate collection, separation, and preparation of the sample for derivatization and analysis.Type: GrantFiled: March 15, 2013Date of Patent: June 30, 2015Inventors: Fred Regnier, Jinhee Kim, Jiri Adamec, Timothy E. Woenker, Richard P. Zoltek, Wenchu Yang
-
Patent number: 9057107Abstract: Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.Type: GrantFiled: March 8, 2012Date of Patent: June 16, 2015Assignee: King Abdullah University of Science and TechnologyInventors: Vladimir Bajic, Mandeep Kaur
-
Patent number: 9046495Abstract: The present invention relates to a non-toxic dipolar solvent for chromogenic substrate for detecting presence of lacZ gene and/or gene activity, which comprises a stabilizing amount of a solubilizing agent. The present invention also relates to a method for inducing lac operon in screening assay, comprising the step of contacting an agar plate with at least one essential oil in a concentration sufficient to induce the lac operon. The present invention further relates to a method for detecting the presence of bacteria, comprising the step of contacting an agar plate with at least one essential oil in a concentration sufficient to induce detection of the bacteria.Type: GrantFiled: August 5, 2013Date of Patent: June 2, 2015Assignee: Pierce Biotechnology, Inc.Inventors: Pierre Sévigny, Martina Bielefeld-Sévigny
-
Patent number: 9040521Abstract: Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating a tauopathy are also provided.Type: GrantFiled: September 15, 2010Date of Patent: May 26, 2015Assignee: THE J. DAVID GLADSTONE INSTITUTESInventor: Li Gan
-
Publication number: 20150140552Abstract: The present invention related to a quantitative assay device and a method for the determination of an analyte, based on a test strip, which contains a porous test membrane allowing for capillary flow of the analyte and complexes of the analyte, a porous upstream membrane in fluid connection with the test membrane and a porous downstream membrane in fluid connection with the test membrane, wherein the test membrane contains two bands having deposited on there high and low concentrations of different calibrator agents and a test band capable of reacting with conjugated analyte complexes giving rise to a measurable signal.Type: ApplicationFiled: November 13, 2014Publication date: May 21, 2015Inventor: Jin Po LEE
-
Patent number: 9029092Abstract: Methods, reagents, kits and systems are disclosed for determining an analyte in a sample suspected of containing the analyte where all reagents are soluble in aqueous solution. One assay method includes treating a sample suspected of containing the analyte under conditions such that if the analyte is present, an activator is brought into reactive configuration with a chemiluminescent compound to activates it. The sample is also treated with an agent to reduce signal not related to analyte. Finally, the sample is treated with a trigger solution thereby producing light from the activated chemiluminescent compound. No reagents are associated with a surface or other solid phase.Type: GrantFiled: February 26, 2010Date of Patent: May 12, 2015Assignee: Beckman Coulter, Inc.Inventors: Hashem Akhavan-Tafti, Dean G. Binger, Ying Chen, Renuka De Silva, Terri McLernon, James Mendoza, Bruce H. Odegaard, Michael Salvati, Nir Shapir, Wenhua Xie
-
Publication number: 20150118676Abstract: Electrokinetic devices and methods are described with the purpose of collecting assayable agents from a dielectric fluid medium. Electrokinetic flow may be induced by the use of plasma generation at high voltage electrodes and consequent transport of charged particles in an electric voltage gradient. In one embodiment, an ionic propulsion device for providing a sample for a bio-specific assay of aerosol particles comprises a housing receiving a sample of aerosol particles and enclosing a high voltage electrode to generate a plasma of electrically charged particles. A carrier assembly is removably receivable in the housing, the carrier assembly comprising a non-conductive carrier and an electrode removably secured to the carrier.Type: ApplicationFiled: August 22, 2014Publication date: April 30, 2015Inventor: Julian Gordon
-
Patent number: 9012155Abstract: The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.Type: GrantFiled: July 22, 2013Date of Patent: April 21, 2015Assignee: Benovus Bio, Inc.Inventor: Eric W. Olle
-
Patent number: 9012136Abstract: There is provided mechanisms for the detection of an analyte in a sample. The mechanisms utilize at least a first measurement channel comprising a detection reactant corresponding to the analyte to be detected, and at least a microstructure associated with the first measurement channel. When the mechanisms are in use, the sample is introduced into the first measurement channel and propagated by way of the first measurement channel towards the microstructure. If the analyte is present in the sample, the analyte interacts with the detection reactant to form a networked product, and the microstructure is configured to filter the networked product.Type: GrantFiled: October 30, 2008Date of Patent: April 21, 2015Assignee: International Business Machines CorporationInventors: Emmanuel Delamarche, Daniel J. Solis
-
Publication number: 20150104810Abstract: The present invention discloses analyte detection devices for detecting one or more analytes present in test samples, especially biological samples. In particular, the devices of the invention are lateral flow assay devices comprising immobilized metal nanoparticle conjugates as the detection means. Methods of using the devices and kits comprising the devices are also described.Type: ApplicationFiled: August 26, 2014Publication date: April 16, 2015Inventors: Rajesh K. Mehra, Kenneth P. ARON
-
Publication number: 20150104809Abstract: The present invention relates to a method for diagnosing, evaluating the prognosis of a cancer patient and evaluating the aggressiveness of a cancer. The methods comprise detecting the phosphorylation status of a Scribble protein, a fragment or variant thereof, wherein the phosphorylation status is indicative of cancer, prognosis and the aggressiveness of a cancer. In one embodiment the cancer is breast cancer.Type: ApplicationFiled: October 16, 2013Publication date: April 16, 2015Applicant: University of Essex Enterprises Ltd.Inventor: Metodi Vladimirov Metodiev
-
Publication number: 20150104455Abstract: Compositions and methods for treating and diagnosing acute myocardial infarction are described. The invention also provides a method of treating an individual to prevent or inhibit damage to myocardial tissue from an acute myocardial infarction comprising administering to the individual an antibody to BMP-1-3, or an antibody to BMP-1-4, or a combination of an antibody BMP-1-3 and an antibody to BMP-1-4 prior to AMI.Type: ApplicationFiled: April 25, 2013Publication date: April 16, 2015Inventors: Slobodan Vukicevic, Lovorka Grgurevic, Ivo Dumic-Cule
-
Publication number: 20150105286Abstract: In this invention, a novel protein interaction domain is provided along with several of its variants. This domain is involved in protein-protein interactions with the Bcl-2 family of proteins. It is named BLID (Bcl2 family of proteins Like Interaction Domain). Several BLID peptides that could be useful for discovery of drugs to help fight pathological states like cancer are presented.Type: ApplicationFiled: October 7, 2014Publication date: April 16, 2015Inventor: Carlos Witte-Hoffmann
-
Publication number: 20150104817Abstract: Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol.Type: ApplicationFiled: December 16, 2014Publication date: April 16, 2015Applicant: ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC.Inventors: Michael C. Mullenix, Robert Elliot Zipkin, Jeffrey Kroll Adams, Wayne Forrest Patton, James J. Donegan
-
Patent number: 9005887Abstract: There is provided mechanisms for the detection of an analyte in a sample. The mechanisms utilize at least a first measurement channel comprising a detection reactant corresponding to the analyte to be detected, and at least a microstructure associated with the first measurement channel. When the mechanisms are in use, the sample is introduced into the first measurement channel and propagated by way of the first measurement channel towards the microstructure. If the analyte is present in the sample, the analyte interacts with the detection reactant to form a networked product, and the microstructure is configured to filter the networked product.Type: GrantFiled: April 30, 2012Date of Patent: April 14, 2015Assignee: International Business Machines CorporationInventors: Emmanuel Delamarche, Daniel J. Solis
-
Publication number: 20150094218Abstract: An in vitro method and a kit for the quantification of antibodies anti-beta amyloid protein in a sample of cerebrospinal fluid comprising the following steps a) concentrating the quantity of said antibodies of said sample with magnetic micro beads coated with macromolecules capable of binding said antibodies b) analysing the concentrated sample obtained in step a) by immunoenzyme assay or by radioimmunoassay; c) analysing a sample comprising antibodies anti-beta amyloid protein having a known titre with the same assay used in step b) and elaborating the related calibration curve, wherein said antibody having a known titre is a murine antibody belonging to the IgG2a or IgG2b class or a human or humanized antibody belonging to the IgG2b or IgGi class.Type: ApplicationFiled: March 20, 2013Publication date: April 2, 2015Applicant: UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCAInventors: Fabrizio Piazza, Carlo Ferrarese
-
Patent number: 8992860Abstract: The present invention relates to systems and methods for minimizing or eliminating diffusion effects. Diffused regions of a segmented flow of multiple, miscible fluid species may be vented off to a waste channel, and non-diffused regions of fluid may be preferentially pulled off the channel that contains the segmented flow. Multiple fluid samples that are not contaminated via diffusion may be collected for analysis and measurement in a single channel. The systems and methods for minimizing or eliminating diffusion effects may be used to minimize or eliminate diffusion effects in a microfluidic system for monitoring the amplification of DNA molecules and the dissociation behavior of the DNA molecules.Type: GrantFiled: April 14, 2014Date of Patent: March 31, 2015Assignee: Canon U.S. Life Sciences, Inc.Inventors: Brian Murphy, Scott Corey, Alex Flamm, Ben Lane, Conrad Laskowski, Chad Schneider
-
Patent number: 8986939Abstract: Methods for assessing the condition of keratinized structures, including hair, in particular methods to determine the condition of keratinized structures in relation to suitability for analysis of analytes of interest in a test sample, are presented. The methods comprise contacting the keratinized structure with a non-proteolytic reducing agent and an optional proteolytic agent. The methods further include inspection of the hair sample, or measurement of free protein eluted from the keratinized structure, after reduction and optional proteolysis to determine condition prior to analyte identification and quantitation by known techniques such as immunoassays.Type: GrantFiled: August 28, 2014Date of Patent: March 24, 2015Assignee: Psychemedics CorporationInventors: Virginia Hill, Michael I. Schaffer, Elvan Loni, Gary Neil Stowe
-
Patent number: 8980572Abstract: A method for generating and localizing a signal in a solid phase substrate detection system comprises applying a solution of target material to a substrate; binding the target with a specific affinity molecule having an attached label, the label comprising multiple signal precursor molecules; applying a carrier to the substrate, and treating the label to convert the signal precursor molecules to signal generating molecules. The carrier comprises solvent for the label and thickener for localizing the signal. The carrier may include developer that converts signal precursor molecules to signal generating molecules. Developer is not necessary if the signal precursor molecules are converted to signal generating molecules by e.g. temperature change, pH change, sonication, light irradiation, microwave heating. A test device for detecting target in a fluid sample, and a kit of parts for determining the presence of target in a fluid sample are also disclosed.Type: GrantFiled: June 14, 2010Date of Patent: March 17, 2015Assignee: Supernova Diagnostics, Inc.Inventors: Ling Wai Wong, Pui Yee Cangel Chan, Wing Cheung Mak, King Keung Sin, Reinhard Renneberg
-
Publication number: 20150072886Abstract: The present invention is based on the discovery that MHC heavy chain monomers immobilized to a solid surface are still capable of forming detectable conformational epitopes and being detected by conformation-dependent antibodies. Methods for detecting peptide binding to HLA monomers, and methods for measuring the relative degree of binding between two MHC-binding peptides as well as a method of measurement for the rate of dissociation of peptides from MHC complexes are provided. The present invention also provides systems and kits useful for conducting the methods of the present invention.Type: ApplicationFiled: July 21, 2014Publication date: March 12, 2015Inventors: Felix A. Montero-Julian, Sylvain Monseaux
-
Patent number: 8975032Abstract: The object of the present invention is to provide: a test kit for an antibody titer or an antibody against a periodontal disease-causing bacterium in a blood sample, which enables the testing on a periodontal disease in patients having a wide scope of immunotypes with high accuracy and can be treated by an automated device at a high speed; a periodontal disease-causing bacterium antigen protein which can be suitably used in the kit; a method for testing an antibody titer or the presence of an antibody in a blood sample using the kit; and a kit for typing strains of Porphyromonas gingivalis.Type: GrantFiled: October 18, 2011Date of Patent: March 10, 2015Assignee: Sunstar Inc.Inventor: Mikio Nozoe
-
Publication number: 20150064719Abstract: Methods for assessing the condition of keratinized structures, including hair, in particular methods to determine the condition of keratinized structures in relation to suitability for analysis of analytes of interest in a test sample, are presented. The methods comprise contacting the keratinized structure with a non-proteolytic reducing agent and an optional proteolytic agent. The methods further include inspection of the hair sample, or measurement of free protein eluted from the keratinized structure, after reduction and optional proteolysis to determine condition prior to analyte identification and quantitation by known techniques such as immunoassays.Type: ApplicationFiled: August 28, 2014Publication date: March 5, 2015Inventors: Virginia Hill, Michael I. Schaffer, Elvan Loni, Gary Neil Stowe
-
Patent number: 8969023Abstract: Aspects of the invention relate to methods and compositions for treating Alzheimer's disease (AD). In some embodiments, the invention provides methods for screening and identifying compounds that selectively inhibit the targeting of the insulin-Akt signaling pathway by A? oligomers.Type: GrantFiled: June 10, 2009Date of Patent: March 3, 2015Assignee: Eleanore Bennett Charitable Trust #2Inventor: Henry W. Querfurth
-
Publication number: 20150056634Abstract: Methods and compositions for preparing dry formulations of Glucose Binding Proteins (GBPs) are disclosed. The GBPs may be stored as a dry formulation without significant loss of activity. After reconstitution, the GBPs may be used to determine the glucose concentration of a sample.Type: ApplicationFiled: March 28, 2013Publication date: February 26, 2015Applicant: Becton, Dickinson and CompanyInventors: Matthew S. Ferriter, Javier Alarcon, Glenn P. Vonk, Melody M.H. Kuroda, Mark Foster Sistare, Brandi Marie Ford
-
Patent number: 8961898Abstract: The present invention provides a bilayer membrane produced using a microchannel capable of easily forming bilayer membranes such as planar lipid bilayer membranes in large quantities, and a production method thereof. A process for producing a bilayer membrane of the present invention comprises forming a state where two liquid phases or liquid and gaseous phases each containing amphipathic molecules are alternately arranged in a microchannel, discharging one of the two liquid phases or the gaseous phase of the liquid and gaseous phases through branch minichannels formed in the wall on one side or in the walls on both sides to contact the remaining liquid phases adjacent to each other, and thereby forming a side-by-side arrangement of bilayer membranes comprising the amphipathic molecules.Type: GrantFiled: March 28, 2008Date of Patent: February 24, 2015Assignee: Tokyo Institute of TechnologyInventors: Takasi Nisisako, Takahiro Baba
-
Patent number: 8962260Abstract: A lateral flow assay is capable of detecting and differentiating viral and bacterial infections. A combined point of care diagnostic device tests markers for viral infection and markers for bacterial infection, to effectively assist in the rapid differentiation of viral and bacterial infections. In some preferred embodiments, bimodal methods and devices determine if an infection is bacterial and/or viral. A dual use two strip sample analysis device includes a first lateral flow chromatographic test strip to detect MxA and a low level of C-reactive protein and a second lateral flow chromatographic test strip to detect high levels of C-reactive protein. In some preferred embodiments, the sample is a fingerstick blood sample.Type: GrantFiled: March 8, 2013Date of Patent: February 24, 2015Assignee: Rapid Pathogen Screening, Inc.Inventors: Robert P. Sambursky, Robert W. VanDine, Uma Mahesh Babu, Peter Condon
-
Patent number: 8962257Abstract: The invention relates to methods of diagnosing the severity of heart failure or a cardiac dysfunction in a subject. The invention further relates to monitoring the severity of heart failure in a subject and determining the prognosis of a subject that has suffered from heart failure. This invention also relates methods to identify patients at risk for cardiac dysfunction when exposed to cardiotoxic chemotherapy agents.Type: GrantFiled: March 8, 2011Date of Patent: February 24, 2015Assignee: The Trustees of the University of PennsylvaniaInventors: Bonnie Ky, Thomas Cappola, Douglas B. Sawyer
-
Patent number: 8956811Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.Type: GrantFiled: July 15, 2013Date of Patent: February 17, 2015Assignee: Genentech Inc.Inventors: Kang Li, Sek Chung Fung, Zhengbin Yao
-
Publication number: 20150045407Abstract: One aspect of the invention provides a method for treating a clinical condition associated with inappropriate or abnormal activation of HER3/ErbB3. In some embodiments, the method of the invention inhibits interaction between MTK1 and actin.Type: ApplicationFiled: August 6, 2014Publication date: February 12, 2015Applicant: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Richard R. Vaillancourt, James J. Sollome
-
Publication number: 20150044693Abstract: Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam.Type: ApplicationFiled: August 13, 2014Publication date: February 12, 2015Inventors: Johnny Jose Valdez, Byung Sook Moon, Ki Chung, Alejandro A. Orozco
-
Publication number: 20150031045Abstract: Disclosed herein are markers for diagnosing amyotrophic lateral sclerosis (ALS) and for monitoring efficacy of treatment for ALS. These markers allow for early detection of ALS, namely before the onset of clinical symptoms. Also disclosed herein are methods for diagnosing ALS in a subject in need thereof, for monitoring the efficacy of a treatment for ALS in the subject, and for treatment of ALS the subject.Type: ApplicationFiled: October 10, 2014Publication date: January 29, 2015Inventors: Eva Chin, Dapeng Chen
-
Patent number: 8940489Abstract: Disclosed are a monoclonal antibody against human D-dimer produced in a mouse and high molecular weight cross-linked fibrin including a corresponding epitope, a cell line secreting the monoclonal antibody, and methods for producing the same. The anti-D-dimer monoclonal antibody of the present invention may be effectively used as a diagnotic agent for screening and detecting in-vivo D-dimer, and high molecular weight cross-linked fibrin and its derivatives containing the D-dimer since the monoclonal antibody specifically reacts with D-dimer, and cross-linked fibrin and its derivatives containing the D-dimer, which do not bind to human fibrinogen or fibrin.Type: GrantFiled: April 22, 2009Date of Patent: January 27, 2015Inventors: Hyun-Ju Doh, Doo-Sik Kim, Kwang-Hoe Chung
-
Publication number: 20150024405Abstract: This disclosure relates to compositions that enhance the deposition of detectable moieties on tissue samples, methods utilizing these compositions and kits including these compositions. The compositions include a deposition enhancer having a formula where R1, R2, R3, and R4 are independently selected from aliphatic, aryl, halogen, a heteroatom-containing moiety, and hydrogen; R1 and/or R3 can be bound to R2 to form a fused, aromatic ring system; R5 is selected from a heteroatom-containing moiety; A is selected from, a carbon atom, a heteroatom, other than sulfur, and any combination thereof; n is 1-5, an enzyme, a specific binding moiety and a detectable moiety.Type: ApplicationFiled: October 6, 2014Publication date: January 22, 2015Applicant: Ventana Medical Systems, Inc.Inventors: Eric J. May, Adrian E. Murillo, Jerome W. Kosmeder, II
-
Publication number: 20150024404Abstract: The present invention provides assays for detecting and measuring the presence or level of anti-TNF? drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF? drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.Type: ApplicationFiled: July 21, 2014Publication date: January 22, 2015Inventors: Sharat Singh, Shui Long Wang, Linda Ohrmund